Oil prices fall as key Russian port resumes loadings, easing supply risks
Investing.com - BTIG raised its price target on MDxHealth SA (NASDAQ:MDXH) to $7.00 from $6.00 on Thursday, while maintaining a Buy rating on the stock, citing strong test volume growth and future revenue potential. The new target sits within the analyst range of $4.20 to $8.00, though InvestingPro data suggests the stock is slightly overvalued at its current price of $4.12.
The research firm highlighted MDxHealth’s significant 65% year-over-year increase in liquid-based test volumes during the third quarter, driven by strength in its Resolve test and new contributions from the recently acquired ExoDx test from Bio-Techne.
BTIG noted that MDxHealth projects accelerating revenue growth in 2026, with a potential path to achieve 30% growth, despite near-term integration challenges as the company adjusts sales territories, converts Select test customers to ExoDx, and phases out its germline test. InvestingPro data shows MDxHealth already achieved 22.56% revenue growth over the last twelve months, with a healthy gross profit margin of 63.53%.
The firm described MDxHealth as "an attractive small-cap growth and value stock" and "a one-stop-shop in personalized prostate diagnostics testing," trading at approximately 1.4 times BTIG’s initial 2027 revenue estimate of $162 million.
This valuation sits below small-cap peers trading at 2x revenue, leading BTIG to suggest MDxHealth is "primed to achieve multiple expansion over the coming quarters."
In other recent news, MDxHealth announced its Q3 2025 earnings, which did not meet analysts’ expectations. The company reported a loss per share of $0.16, which was larger than the anticipated loss of $0.11 per share. Additionally, the revenue for the quarter was $27.4 million, falling short of the projected $28.12 million. Despite these results, the company noted significant year-over-year growth in critical areas. There have been no new updates regarding mergers or acquisitions involving MDxHealth. Analyst firms have not provided any recent upgrades or downgrades for the company. Investors may find these developments noteworthy as they assess the company’s performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.